This Novartis Drug Could Help Delay Dialysis—FDA Grants Full Approval - Novartis (NYSE:NVS)

Novartis gains full FDA nod for Fabhalta in kidney disorder IgAN

With two approved medicines to treat primary immunoglobulin A nephropathy (IgAN) and a third therapy in phase 3 testing, Novartis is on its way to cornering the market for the indication. | The FDA has converted its…